幽门螺杆菌根除时机对早期胃癌治疗后异时性病变风险的影响
该研究基于韩国国民健康保险服务数据库,纳入因早期胃癌接受内镜切除或部分胃切除并接受幽门螺杆菌根除治疗的患者19767例。按根除治疗时机分为切除前、切除后1年内和切除后超过1年三组,分析异时性病变的发生风险。结果显示,切除后1年内根除相比超过1年根除可降低异时性病变风险,而切除前根除与切除后1年内根除风险无差异。
要点
- 早期胃癌治疗后1年内根除幽门螺杆菌可降低异时性病变风险。
- 超过1年才根除者异时性病变风险更高,内镜切除后HR 0.79,手术后HR 0.39。
- 切除前根除与切除后1年内根除在异时性病变风险上无差异。
核心结论
- 早期胃癌治疗后1年内处方幽门螺杆菌根除治疗,相比超过1年才根除,可降低异时性胃肿瘤发生风险,内镜切除和手术患者均获益。
- 切除前根除与切除后1年内根除在异时性病变风险上无差异。
研究设计与样本
- 基于韩国国民健康保险服务数据库的人群队列研究。
- 纳入因早期胃癌接受内镜切除或部分胃切除并接受幽门螺杆菌根除治疗的患者共19767例,其中内镜切除7452例、手术12315例。
- 按幽门螺杆菌根除处方时机分为切除前、切除后1年内、切除后超过1年三组。
主要发现
- 内镜切除后5年异时性病变累积发生率:切除前组14.0%,切除后1年内组12.3%,切除后超过1年组16.9%。
- 再次手术比例:切除前组1.2%,切除后1年内组1.3%,切除后超过1年组2.9%。
- 切除后1年内组异时性病变风险低于切除后超过1年组:内镜切除后HR 0.79(95%CI 0.65-0.95),手术后HR 0.39(95%CI 0.28-0.53)。
- 切除前组与切除后1年内组的异时性病变风险无差异。
关键数值与推荐
- 内镜切除后5年异时性病变累积发生率:切除前14.0%、切除后1年内12.3%、切除后超过1年16.9%。
- 异时性病变风险比较:内镜切除后HR 0.79(95%CI 0.65-0.95);手术后HR 0.39(95%CI 0.28-0.53),均为切除后1年内组对比切除后超过1年组。
- 再次手术比例:切除前1.2%、切除后1年内1.3%、切除后超过1年2.9%。
临床怎么用
- 对接受内镜切除或部分胃切除的早期胃癌患者,应在治疗后1年内处方幽门螺杆菌根除治疗以降低异时性病变风险。
- 不宜将根除治疗延迟至治疗后超过1年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Helicobacter pylori eradication can reduce the risk of metachronous lesions after the treatment of early gastric cancer. We aimed to analyze the impact of the timing of H pylori eradication on metachronous recurrence. METHODS: Data of patients who underwent endoscopic resection or partial gastrectomy for early stage gastric cancer and received H pylori eradication therapy were obtained from the Korean National Health Insurance Service database. Patients were classified into 3 groups according to the timing of the prescription for H pylori eradication: preresection; within 1 year postresection; and >1 year postresection. RESULTS: Among 19,767 patients, 7452 and 12,315 underwent endoscopic resection and surgery, respectively. The 5-year cumulative incidence of metachronous lesions after endoscopic resection was 14.0% in the preresection group, 12.3% in the within 1 year postresection group, and 16.9% in the >1 year postresection group. Surgery was performed in 1.2% of the preresection group, 1.3% of the within 1 year postresection group, and 2.9% of the >1 year postresection group. The within 1 year postresection group had a lower risk of development of metachronous lesions than the >1 year postresection group (hazard ratio [95% confidence interval]: after endoscopic resection, 0.79 [0.65-0.95]; after surgery, 0.39 [0.28-0.53]). The risk of development of metachronous lesions did not differ between the preresection and within 1 year postresection groups. CONCLUSION: Prescription of H pylori eradication therapy within 1 year after gastric cancer treatment reduces the risk of development of metachronous gastric neoplasms compared with a late prescription of eradication therapy in patients undergoing endoscopic resection and those undergoing surgery.
引用
- Kim HJ, Kim YJ, Seo SI, et al. Impact of the timing of Helicobacter pylori eradication on the risk of development of metachronous lesions after treatment of early gastric cancer: a population-based cohort study. Gastrointest Endosc. 2020. PMID: 32473251. doi:10.1016/j.gie.2020.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。